Constructs comprising pH low insertion peptide and variants thereof conjugated to monomethyl auristatins and analogs thereof are described. These constructs are useful, for example, in the treatment of solid tumors, including the treatment of breast cancer and prostate cancer, as well as other cancers such as pancreatic cancer, ovarian cancer, cervical cancer, uterine cancer, lung cancer, skin cancer, kidney cancer, and colon cancer. The constructs inhibit tumor cell proliferation and reduce tumor volume, particularly in a low pH tumor environment.

The present invention provides a stable peptide-conjugated, ascorbic acid derivative, a method for preparing the same, and a cosmetic composition comprising the same as an active ingredient. The stable peptide-conjugated ascorbic acid derivative of the present invention has both the effect of whitening the skin by inhibiting melanin production and the effect of reducing skin wrinkles by activating collagen production, and may be used in a cosmetic composition.

A heat insulation material is provided that is produced by drying a fibrous matrix impregnated with a solution of pseudo-peptides of formula (I), wherein: R is a side-chain of a natural or synthetic amino acid , R1 is either a linear or branched (C.sub.1-C.sub.3)alkyl group, or a linear or branched (C.sub.1-C.sub.3)alcoxy group, or an aryl group, or an aryl(C.sub.1-C.sub.3)alkyl group, or an aryloxy group, or a saturated or unsaturated heterocycle, n=1 or 2, and A is an aromatic or heteroaromatic group with at least one cycle.

A heat insulation material is provided that is produced by drying a fibrous matrix impregnated with a solution of pseudo-peptides of formula (I), wherein: R is a side-chain of a natural or synthetic amino acid , R1 is either a linear or branched (C.sub.1-C.sub.3)alkyl group, or a linear or branched (C.sub.1-C.sub.3)alcoxy group, or an aryl group, or an aryl(C.sub.1-C.sub.3)alkyl group, or an aryloxy group, or a saturated or unsaturated heterocycle, n=1 or 2, and A is an aromatic or heteroaromatic group with at least one cycle.

Disclosed are a novel compound having a higher angiogenic effect than that of a known peptide-based angiogenic agent, and an angiogenic agent including the novel compound. The compound is represented by the following formula [1]: Cyclic(Cys-O2Oc-SVV(F/Y)GLRG-Cys)-NH.sub.2 (wherein the number of oxyethylene units, represented by O2Oc, is within the range of 2 to 6), the following formula [II]: Cyclic(O.sub.2Oc-SVV(F/Y)GLRQ)-NH.sub.2 [II] (wherein the number of oxyethylene units, represented by O2Oc, is within the range of 2 to 6), or the following formula [III]: O.sub.2Oc-SVV(F/Y)GLR-NH.sub.2 [III] (wherein the number of oxyethylene units, represented by O2Oc, is within the range of 2 to 6).

The present disclosure relates to a peptide comprising at least five amino acid residues, wherein at least one amino acid residue is modified to an epsilon-lysine, delta-ornithine, gamma-2,4-diaminobutyric acid, beta-2,3-diaminopropionic acid, with the peptide also comprising at least one non-epsilon lysine, non-delta-ornithine, non-gamma-2,4-diaminobutyric acid or non-beta-2,3-diaminopropionic acid, and wherein the peptide displays a reduced or no cytotoxicity when compared to an equivalent non-modified peptide. In a preferred embodiment, the modifications are to the melittin or mastoparan B peptides, and comprise the substitution of at least one a-lysine residue for an ε-lysine residue, and the modified peptides display antimicrobial activity. The present disclosure is also directed to pharmaceutical compositions, kits, ophthalmic preparations comprising the modified antimicrobial peptides and use of the modified antimicrobial peptides in methods of inhibiting growth of microorganisms, methods of managing microbial colonization, methods of treating proliferative disease, and methods of treating inflammation. The present disclosure also relates to a method of improving the therapeutic index (safety) of an isolated peptide comprising the aforementioned modification.

The peptides of the invention are of formula (I) or (IV). The peptides of the invention are useful in the treatment of cancer.

The peptides of the invention are of formula (I) or (IV). The peptides of the invention are useful in the treatment of cancer.

Provided is a method for modifying a chimeric antigen receptor-modified T cell (CAR-T cell). The method comprises expressing an SCFV-CDS TM-4-1BB-CD3ζ molecule in a T cell. The CAR-T cell prepared using the method can specifically recognize and bind to a tumor cell with elevated expression of a ROBO1 protein, and can be used to prevent and treat a corresponding tumor-related disease.

Provided is a method for modifying a chimeric antigen receptor-modified T cell (CAR-T cell). The method comprises expressing an SCFV-CDS TM-4-1BB-CD3ζ molecule in a T cell. The CAR-T cell prepared using the method can specifically recognize and bind to a tumor cell with elevated expression of a ROBO1 protein, and can be used to prevent and treat a corresponding tumor-related disease.